CA2807034C - C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof - Google Patents

C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof Download PDF

Info

Publication number
CA2807034C
CA2807034C CA2807034A CA2807034A CA2807034C CA 2807034 C CA2807034 C CA 2807034C CA 2807034 A CA2807034 A CA 2807034A CA 2807034 A CA2807034 A CA 2807034A CA 2807034 C CA2807034 C CA 2807034C
Authority
CA
Canada
Prior art keywords
phenyl
chloro
mmol
methoxy
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2807034A
Other languages
English (en)
French (fr)
Other versions
CA2807034A1 (en
Inventor
Fanglong Yang
Peng Cho Tang
Qing Dong
Wangyang Tu
Jiang Fan
Dongliang Guan
Guangyuan Shen
Yang Wang
Jijun Yuan
Limin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CA2807034A1 publication Critical patent/CA2807034A1/en
Application granted granted Critical
Publication of CA2807034C publication Critical patent/CA2807034C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2807034A 2010-08-10 2011-06-30 C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof Active CA2807034C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201010249618.3 2010-08-10
CN201010249618 2010-08-10
CN2010105896065A CN102372722A (zh) 2010-08-10 2010-12-06 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
CN201010589606.5 2010-12-06
PCT/CN2011/076680 WO2012019496A1 (zh) 2010-08-10 2011-06-30 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CA2807034A1 CA2807034A1 (en) 2012-02-16
CA2807034C true CA2807034C (en) 2019-05-07

Family

ID=45567352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2807034A Active CA2807034C (en) 2010-08-10 2011-06-30 C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof

Country Status (11)

Country Link
US (1) US8609622B2 (OSRAM)
EP (1) EP2604612B1 (OSRAM)
JP (1) JP5984808B2 (OSRAM)
KR (1) KR101862891B1 (OSRAM)
CN (2) CN102372722A (OSRAM)
BR (1) BR112013002125A2 (OSRAM)
CA (1) CA2807034C (OSRAM)
ES (1) ES2581728T3 (OSRAM)
MX (1) MX2013001098A (OSRAM)
RU (1) RU2606501C2 (OSRAM)
WO (1) WO2012019496A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2703396B1 (en) * 2011-04-25 2016-06-22 Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
WO2013038429A2 (en) 2011-09-13 2013-03-21 Panacea Biotec Ltd. Novel sglt inhibitors
CN102627535A (zh) * 2012-03-31 2012-08-08 天津药物研究院 含1,1-二苯基环丙基结构的化合物的制备方法
WO2013178064A1 (zh) * 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
EP3466431B1 (en) 2013-03-14 2023-11-15 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
CN104151306A (zh) * 2013-05-13 2014-11-19 北京新天宇科技开发有限公司 一种坎格列净的新的制备方法
CN104619713B (zh) * 2013-05-24 2017-06-16 四川海思科制药有限公司 氧杂双环衍生物、制备方法及其应用
WO2014206349A1 (zh) * 2013-06-28 2014-12-31 四川海思科制药有限公司 氧杂-硫杂-双环[3.2.1]辛烷衍生物、制备方法及其用途
CN107311992B (zh) * 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
CN104447893B (zh) * 2013-09-25 2018-01-23 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
ES2605886T3 (es) * 2013-09-27 2017-03-16 Sunshine Lake Pharma Co., Ltd. Derivados de glucopiranosilo y sus usos en medicina
EP3089969A2 (en) * 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
PL3145934T3 (pl) 2014-05-19 2021-08-16 Pfizer Inc. Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN105294785A (zh) * 2014-07-02 2016-02-03 上海阳帆医药科技有限公司 C-苯并五元杂芳环类芳基葡萄糖苷衍生物及其制备方法与用途
US20160002275A1 (en) * 2014-07-03 2016-01-07 Cadila Healthcare Limited Process for preparation and purification of canagliflozin
CN104119324B (zh) * 2014-07-23 2016-03-30 齐鲁天和惠世制药有限公司 一种卡格列净的制备方法
CN105461762B (zh) * 2014-09-27 2018-12-04 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
BR112017005454A2 (pt) * 2014-09-30 2017-12-12 Jiangsu Hengrui Medicine Co composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
EP3226874A1 (en) * 2014-12-03 2017-10-11 Sun Pharmaceutical Industries Ltd Processes for the preparation of ertugliflozin
EP3303345A4 (en) 2015-05-25 2019-01-30 Sun Pharmaceutical Industries Ltd ERTUGLIFOZINE CO-CRYSTALS AND PROCESS FOR PREPARING THEM
KR101987403B1 (ko) * 2016-01-04 2019-06-10 제일약품주식회사 융합 페닐 환이 포함된 c-글루코시드 유도체 또는 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
CN106955273B (zh) * 2016-01-11 2020-10-20 江苏恒瑞医药股份有限公司 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物
CN107686496B (zh) * 2016-08-05 2021-01-19 江苏恒瑞医药股份有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
CN106674245B (zh) * 2017-01-10 2019-07-26 北京中海康医药科技发展有限公司 吡喃葡萄糖基衍生物的制备及医药上的应用
CN109549939A (zh) * 2017-09-26 2019-04-02 江苏恒瑞医药股份有限公司 Sglt2抑制剂和dpp-4抑制剂联合在制备治疗糖尿病的药物中的用途
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2021121270A1 (zh) * 2019-12-19 2021-06-24 上海研健新药研发有限公司 一种SGLTs抑制剂的纯化方法及其应用
CN113004349A (zh) * 2019-12-19 2021-06-22 上海研健新药研发有限公司 一种SGLTs抑制剂的制备方法及其关键中间体
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
EP4161912A1 (en) 2020-06-05 2023-04-12 KRKA, d.d., Novo mesto Preparation of highly pure amorphous dapagliflozin
CN114195748B (zh) * 2020-09-17 2023-11-14 上海森辉医药有限公司 一种钠-葡萄糖协同转运蛋白2抑制剂的制备方法
CN112375087A (zh) * 2020-11-27 2021-02-19 浙江天宇药业股份有限公司 一种脯氨酸恒格列净的合成方法
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法
CN116785268A (zh) * 2022-03-14 2023-09-22 江苏万邦生化医药集团有限责任公司 一种sglt-2抑制剂的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
CA2444481A1 (en) * 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ES2567571T3 (es) * 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
KR100942622B1 (ko) * 2003-08-01 2010-02-17 미쓰비시 타나베 파마 코퍼레이션 나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
WO2008034859A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CN101790311B (zh) 2007-08-23 2014-04-23 泰拉科斯有限公司 苄基苯衍生物及使用方法
AR072511A1 (es) * 2008-07-15 2010-09-01 Theracos Inc Derivados deuterados de bencilbenceno y metodos de uso. composicion farmaceutica.
TWI482779B (zh) 2008-08-22 2015-05-01 Theracos Inc Ｓｇｌｔ２抑制劑之結晶型
CN102149717B (zh) 2008-08-28 2014-05-14 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010074219A1 (ja) * 2008-12-26 2010-07-01 アステラス製薬株式会社 ベンゾチオフェン化合物
WO2011051864A1 (en) * 2009-11-02 2011-05-05 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
AR086922A1 (es) * 2011-06-13 2014-01-29 Panacea Biotec Ltd Derivados de 3,4,5-trihidroxi-6-(hidroximetil)tetrahidro-2h-pirano utiles para el tratamiento de diabetes y dislipidemias, composiciones farmaceuticas que los contienen y metodo para prepararlos

Also Published As

Publication number Publication date
KR20130095741A (ko) 2013-08-28
ES2581728T3 (es) 2016-09-07
JP5984808B2 (ja) 2016-09-06
CN102482290A (zh) 2012-05-30
MX2013001098A (es) 2013-06-05
HK1167395A1 (en) 2012-11-30
WO2012019496A1 (zh) 2012-02-16
CN102482290B (zh) 2014-01-15
RU2606501C2 (ru) 2017-01-10
EP2604612A1 (en) 2013-06-19
CA2807034A1 (en) 2012-02-16
KR101862891B1 (ko) 2018-05-30
EP2604612A4 (en) 2013-07-24
US8609622B2 (en) 2013-12-17
EP2604612B1 (en) 2016-04-20
BR112013002125A2 (pt) 2016-05-24
RU2013107748A (ru) 2014-09-20
US20130130997A1 (en) 2013-05-23
JP2013533291A (ja) 2013-08-22
CN102372722A (zh) 2012-03-14

Similar Documents

Publication Publication Date Title
CA2807034C (en) C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof
AU2014317663B2 (en) C-aryl glucoside derivative, preparation method for same, and medical applications thereof
AU2010309833B2 (en) Glycoside derivatives and uses thereof
KR101719758B1 (ko) 씨 글루코사이드 유도체
JP6450769B2 (ja) グルコピラノシル誘導体及びその医薬品における使用
AU2004288822A1 (en) 4-Biarylyl-1-phenylazetidin-2-ones
KR101513234B1 (ko) Sglt2 억제제로서의 신규 티오펜 유도체 및 이를 포함하는 약학 조성물
JP6667008B2 (ja) 融合フェニル環が含まれたｃ−グルコシド誘導体またはその薬学的に許容可能な塩、その製造方法、およびそれを含む薬学的組成物
TWI510491B (zh) Ｃ－芳基葡萄糖苷衍生物、其製備方法及其在醫藥上的應用
HK1227881A1 (en) C-aryl glucoside derivative, preparation method for same, and medical applications thereof
HK1167395B (en) C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160601